

**GILEAD SCIENCES, INC.**  
**RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION**

(unaudited)

(in thousands, except per share amounts)

Below is a reconciliation of Gilead's GAAP operating results and diluted per share amounts as reported in the press release dated January 23, 2008. Non-GAAP net income and net income per diluted share for the 2007 periods are presented excluding the impact of after-tax stock-based compensation expense and the related methodology for deriving dilutive securities. Non-GAAP net income and net income per diluted share for the 2006 periods are presented excluding the impact of the purchased in-process research and development expenses incurred in connection with the acquisitions of Corus Pharma, Inc. and Myogen, Inc. as well as the impact of the after-tax stock-based compensation expense and the related methodology for deriving dilutive securities. Management believes this non-GAAP information is useful for investors, taken in conjunction with Gilead's GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company's operating results as reported under GAAP.

	Three Months Ended December 31,		Year Ended December 31,	
	2007	2006	2007	2006
Net income (loss) (GAAP)	\$ 401,642	\$ (1,665,647)	\$ 1,615,298	\$ (1,189,957)
Purchased in-process research and development expenses	-	2,038,483	-	2,394,051
Stock-based compensation expense, net of tax	25,121	24,904	131,344	101,708
Net income (Non-GAAP)	<u>\$ 426,763</u>	<u>\$ 397,740</u>	<u>\$ 1,746,642</u>	<u>\$ 1,305,802</u>
Shares used in per share calculation - diluted (GAAP)	969,274	920,198	964,356	918,212
Dilutive securities	<u>2,227</u>	<u>39,073</u>	<u>2,123</u>	<u>39,792</u>
Shares used in per share calculation - diluted (Non-GAAP)	<u>971,501</u>	<u>959,271</u>	<u>966,479</u>	<u>958,004</u>
Net income (loss) per share - diluted (GAAP)	<u>\$ 0.41</u>	<u>\$ (1.81)</u>	<u>\$ 1.68</u>	<u>\$ (1.30)</u>
Net income per share - diluted (Non-GAAP)	<u>\$ 0.44</u>	<u>\$ 0.41</u>	<u>\$ 1.81</u>	<u>\$ 1.36</u>